Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Immunology of the Infection Perinatal (EP38)

This study has been completed.
Sponsor:
Collaborators:
Institut Pasteur
University of Paris 5 - Rene Descartes
Hôpital Necker-Enfants Malades
Information provided by:
French National Agency for Research on AIDS and Viral Hepatitis
ClinicalTrials.gov Identifier:
NCT01055873
First received: December 24, 2009
Last updated: November 17, 2010
Last verified: November 2010

December 24, 2009
November 17, 2010
February 2007
February 2009   (final data collection date for primary outcome measure)
To describe the immune and virological status of perinatally infected patients that are above 15 yrs old and [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01055873 on ClinicalTrials.gov Archive Site
To study their associations with the current virological/clinical and therapeutic status, the duration of uncontrolled viremia (defined by treatment history), the virological, immunological (CD4+ numbers), and clinical status [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
Immunology of the Infection Perinatal
Immunology of the Infection Perinatal

ANRS-EP38-IMMIP is a non interventional study. A single blood sample (30 mL) was drawn during a hospital visit for clinical follow-up. Immunological assays were performed on fresh blood. Cells and plasma were stored and kept frozen for additional biological evaluations.

Patients are included in the French perinatal cohort (ANRS CO-10), or have been followed since before 1996 in the same clinical sites as patients who belong to ANRS CO-10. In the ANRS CO-10 cohort, all patients are prospectively followed from birth.

Purpose:

Efficient anti-retroviral treatments lead to a significantly increased life expectancy. Children with perinatal infection are now reaching adulthood. The deleterious impact of viral replication during ontogenesis of the immune system, and the high thymic activity during the early years of life, preclude an extrapolation from data pertaining to the adult immune status and mean that specific pediatric studies are required. No data are available concerning the immune status of adolescents or young adults infected via materno-foetal transmission.

Detailed description:

Our assumption is that the duration of uncontrolled viral replication will affect the immune status after treatment because viral replication is associated with:

  1. disease progression independently of CD4+ T cell levels;
  2. accelerated senescence of the immune system;
  3. destruction of organs involved in the restoration of major immune cell populations.

The aims of the study are:

  1. to describe the immune and virological status of perinatally infected patients that are above 15 yrs old and
  2. to study their associations with :

    1. the current virological/clinical and therapeutic status,
    2. the duration of uncontrolled viremia (defined by treatment history),
    3. the virological, immunological (CD4+ numbers), and clinical status at time of HAART initiation.

The immune status will be defined by (1) the number and phenotype of CD4+ and CD8+ T lymphocytes, dendritic cells, regulatory T cells, and NK cells, (2) the functions (proliferation and cytokine production) of CD4+ and CD8+ lymphocytes that are specific for HIV, a recall antigen (tetanus toxoid) and other viruses (CMV, EBV and Flu),the repertoire of Natural Killer cell receptors.

The virological status will be defined by the level of HIV DNA in PBMCs, the HIV subtype, resistance mutations in archived and circulating virus and sequences of the regions of the viral envelope involved in co-receptor use.

Clinical, therapeutic, demographic, virological and immunological data are collected from birth for members of the ANRS CO-10 cohort, and will be collected retrospectively since diagnosis for non-included patients.

Observational
Not Provided
Not Provided
Retention:   Samples With DNA
Description:

..

Non-Probability Sample

Patients are included in the French perinatal cohort (ANRS CO-10), or have been followed since before 1996 in the same clinical sites as patients who belong to ANRS CO-10. In the ANRS CO-10 cohort, all patients are prospectively followed from birth

HIV Infections
Biological: A single blood sample (30 mL)
A single blood sample (30 mL) was drawn during a hospital visit for clinical follow-up. Immunological assays were performed on fresh blood. Cells and plasma were stored and kept frozen for additional biological evaluations
Not Provided
Avettand-Fenoel V, Blanche S, Le Chenadec J, Scott-Algara D, Dollfus C, Viard JP, Bouallag N, Benmebarek Y, Rivière Y, Warszawski J, Rouzioux C, Buseyne F. Relationships between HIV disease history and blood HIV-1 DNA load in perinatally infected adolescents and young adults: the ANRS-EP38-IMMIP study. J Infect Dis. 2012 May 15;205(10):1520-8. doi: 10.1093/infdis/jis233. Epub 2012 Mar 15. PubMed PMID: 22427678.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
93
February 2009
February 2009   (final data collection date for primary outcome measure)

Inclusion criteria

  • Being included in the ANRS CO-10 cohort, or being followed in the same sites as such patients since before 1996
  • Being followed in the Paris area
  • HIV-1 infected through the perinatal route, and not HIV-2 co-infected
  • No therapeutic changes for at least 6 months; single molecule change without modification of viral load is tolerated.
  • Informed consent signed by the patients and by their legal guardians for those younger than 18.
  • Being affiliated to the Exclusion criteria French national social security system

Exclusion criteria

- Not Being affiliated to the French national social security system

Both
15 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT01055873
2006-AO142-49
No
Lucie Marchand/Project manager, French National Agency for Research on AIDS and Viral Hepatitis
French National Agency for Research on AIDS and Viral Hepatitis
  • Institut Pasteur
  • University of Paris 5 - Rene Descartes
  • Hôpital Necker-Enfants Malades
Study Chair: Warszawski MD Josiane, Methodologist INSERM U 822, Hôpital de Bicêtre, portes 10 à 15, 82 rue du Général Leclerc, 94276 Le Kremlin-Bicêtre Cedex warszaws@vjf.inserm.fr ; Tel : 01 45 21 22 86
Principal Investigator: Blanche PHD Stéphane Hopital Necker Enfants malades-Service immunologie hématologie pédiatrique -149 rue de Sèvres- 75015 PARIS 01 44 49 48 24
French National Agency for Research on AIDS and Viral Hepatitis
November 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP